Efficacy of a standardized extract of Matricariae chamomilla L., Melissa officinalis L. and tyndallized Lactobacillus acidophilus (HA122) in infantile colic: An open randomized controlled trial

BackgroundInfant colic (IC) is a prevalent physiological event of infants, which can disrupt the child's home environment. We aimed to investigate the effectiveness of a mixture of Matricariae chamomilla L., Melissa officinalis L. and tyndallized Lactobacillus acidophilus (HA122) compared with Lactobacillus reuteri DSM 17938 and with simethicone for the treatment of IC. MethodsA multicenter randomized comparative study was conducted in infants with colic, according to Rome III criteria, who were randomly assigned to receive M.chamomilla L., M.officinalis L. and tyndallized L.acidophilus (HA122) (Colimil((R)) Plus((R)); Milte Italia Spa, Milan, Italy) (Group A), L.reuteri DSM 17938 (Group B) and simethicone (Group C). Treatment was given to subjects for 28days. Key ResultsOne-hundred and seventy-six patients completed the study. Mean daily crying time at day 28 was significantly lower in group A (-44, 95% CI: -58 to -30, P<.001) and group B (-35, 95% CI: -49 to -20, P<.001) when compared to group C. No significant difference was observed between Group A and Group B (mean difference: -9minutes, 95% CI -23 to +5, P=.205). At day 28, 39 of 57 (68.4%) of infants in Group C responded to the treatment compared with 57 out of 60 patients (95%) of Group A and 51 out of 59 (86.4%) of Group B (P<.001). ConclusionsThis study suggests that administration of M.chamomilla L., M.officinalis L. and tyndallized L.acidophilus (HA122) and L.reuteri DSM 17938 are significantly more effective than simethicone in IC. Clinical Trial Registration: ClinicalTrials.gov: NCT02708238.